Cargando…

Benefit-risk assessment for remdesivir in COVID-19

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290138/
http://dx.doi.org/10.1007/s40278-020-79483-8
_version_ 1783545606257508352
collection PubMed
description
format Online
Article
Text
id pubmed-7290138
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-72901382020-06-12 Benefit-risk assessment for remdesivir in COVID-19 Reactions Weekly Clinical Study Springer International Publishing 2020-06-13 2020 /pmc/articles/PMC7290138/ http://dx.doi.org/10.1007/s40278-020-79483-8 Text en © Springer International Publishing AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Study
Benefit-risk assessment for remdesivir in COVID-19
title Benefit-risk assessment for remdesivir in COVID-19
title_full Benefit-risk assessment for remdesivir in COVID-19
title_fullStr Benefit-risk assessment for remdesivir in COVID-19
title_full_unstemmed Benefit-risk assessment for remdesivir in COVID-19
title_short Benefit-risk assessment for remdesivir in COVID-19
title_sort benefit-risk assessment for remdesivir in covid-19
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290138/
http://dx.doi.org/10.1007/s40278-020-79483-8